Grace Therapeutics, Inc.
GRCE
$3.00
-$0.13-4.15%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 636.00K | -4.16M | -3.43M | -2.62M | -3.17M |
| Total Depreciation and Amortization | 2.00K | 2.00K | 2.00K | 1.00K | 1.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -3.53M | 733.00K | -1.01M | -1.88M | 373.00K |
| Change in Net Operating Assets | -66.00K | -695.00K | 203.00K | 900.00K | 704.00K |
| Cash from Operations | -2.95M | -4.12M | -4.24M | -3.60M | -2.09M |
| Capital Expenditure | -- | -- | -- | -- | -22.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | 1.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 0.00 | 15.00K | 0.00 | -15.00K | 6.57M |
| Cash from Investing | 0.00 | 15.00K | 0.00 | -15.00K | 6.55M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 15.00M | -- | -- | -- | 162.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -967.00K | -- | -- | -- | -162.00K |
| Cash from Financing | 14.03M | -- | -- | -- | 0.00 |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 11.08M | -4.10M | -4.24M | -3.61M | 4.46M |